An Extensive UCSF Study Questions Previous Study’s Analytic Methods San Francisco, CA (PRWEB) May 05, 2012 A popular smoking cessation medication has

A popular smoking cessation medication has been under a cloud of suspicion ever since the Canadian Medical Association Journal (CMAJ) published a study in July 2011 reporting "risk of serious adverse cardiovascular events associated with varenicline."

The smoking cessation drug varenicline significantly reduced alcohol consumption in a group of heavy-drinking smokers.

MENLO PARK, Calif., March 14, 2012 /PRNewswire/ -- In preclinical studies, researchers at SRI International and Astraea Therapeutics have recently evaluated the role of a new drug

Aside from the obvious health issues, smoking can be an expensive habit and yet millions of smokers continue to set light to thousands of dollars a year to support this addiction.